Literature DB >> 24866208

Immunoglobulin-free light chain monomer-dimer patterns help to distinguish malignant from premalignant monoclonal gammopathies: a pilot study.

Batia Kaplan1, Sizilia Golderman, Boris Aizenbud, Konstantin Esev, Olga Kukuy, Merav Leiba, Avi Livneh, Ilan Ben-Zvi.   

Abstract

Multiple myeloma (MM) and AL amyloidosis (AL) are two malignant forms of monoclonal gammopathies. For the purposes of prognosis and treatment, it is important to distinguish these diseases from the premalignant forms of monoclonal gammopathies, such as monoclonal gammopathy of unknown significance (MGUS) and smoldering myeloma (SMM). Routine serum/urine tests for monoclonal protein are insufficient for differential diagnosis. Thus, invasive procedures, such as tissue aspiration or biopsy, are applied. In this study, we aimed at characterization of serum-free light chain (FLC) monomer-dimer patterns to distinguish the malignant from the premalignant forms of monoclonal gammopathies. A quantitative Western blotting was applied to estimate the FLC monomer and dimer levels in AL, MM, MGUS, and SMM patients, and in control subjects (healthy individuals and patients with AA amyloidosis). AL and MM patients displayed an abnormally increased dimerization of monoclonal FLC, accompanied by higher clonality values of FLC dimers, as compared to that of monomers. These abnormalities of FLC patterns were not observed in patients with MGUS, SMM, AA amyloidosis, and healthy individuals. Analysis of FLC patterns helped to differentiate AL and MM from MGUS and SMM, a goal difficult to achieve using routine serum tests. Also, our technique might serve as a complimentary diagnostic tool in the cases with suspected AL amyloidosis, where the diagnosis of MM is excluded, while the results of amyloid typing by routine immunohistochemical techniques are inconclusive.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24866208     DOI: 10.1002/ajh.23773

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  5 in total

1.  Kidney disease and plasma cell dyscrasias: ambiguous cases solved by serum free light chain dimerization analysis.

Authors:  Olga Kukuy; Batia Kaplan; Sizilia Golderman; Alexander Volkov; Adrian Duek; Merav Leiba; Ilan Ben-Zvi; Avi Livneh
Journal:  Clin Exp Nephrol       Date:  2019-02-08       Impact factor: 2.801

2.  A method to obtain purified free light chain monomers and dimers from urine samples of patients with multiple myeloma.

Authors:  Laura Caponi; Alice Botti; Nadia Romiti; Aldo Paolicchi; Maria Franzini
Journal:  Immunol Res       Date:  2022-09-14       Impact factor: 4.505

3.  Immunoglobulin free light chains in saliva: a potential marker for disease activity in multiple sclerosis.

Authors:  B Kaplan; S Golderman; E Ganelin-Cohen; A Miniovitch; E Korf; I Ben-Zvi; A Livneh; S Flechter
Journal:  Clin Exp Immunol       Date:  2017-12-26       Impact factor: 4.330

4.  Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio.

Authors:  Gurmukh Singh
Journal:  J Clin Med Res       Date:  2016-11-24

5.  Comparison of two free light chain assays: performance of the involved free light chain ratio and implications for diagnosis of multiple myeloma.

Authors:  Maria Alice V Willrich; David L Murray; S Vincent Rajkumar; Sandra C Bryant; Dirk Larson; Vanessa Pazdernik; Melissa R Snyder; Robert A Kyle; Angela Dispenzieri
Journal:  Blood Cancer J       Date:  2022-09-02       Impact factor: 9.812

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.